Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Fluticasone propionate (Nasal)
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Fluticasone propionate 50micrograms/dose nasal spray
1202010M0AAACAC
|
Fluticasone propionate (Nasal) | Fluticasone propionate (Nasal) | Ear, Nose and Oropharynx | 147,617 |
|
Flixonase 50micrograms/dose aqueous nasal spray
1202010M0BBACAC
|
Flixonase | Fluticasone propionate (Nasal) | Ear, Nose and Oropharynx | 76,896 |
|
Nasofan 50micrograms/dose aqueous nasal spray
1202010M0BCAAAC
|
Nasofan | Fluticasone propionate (Nasal) | Ear, Nose and Oropharynx | 35,051 |
|
Fluticasone 400microgram/unit dose nasal drops
1202010M0AAABAB
|
Fluticasone propionate (Nasal) | Fluticasone propionate (Nasal) | Ear, Nose and Oropharynx | 25,077 |
|
Flixonase Nasule 400microgram/unit dose nasal drops
1202010M0BBABAB
|
Flixonase | Fluticasone propionate (Nasal) | Ear, Nose and Oropharynx | 8,818 |
|
Nasofan Allergy 50micrograms/dose nasal spray
1202010M0BCABAC
|
Nasofan | Fluticasone propionate (Nasal) | Ear, Nose and Oropharynx | 1,301 |
|
Pirinase Hayfever 0.05% nasal spray
1202010M0BDAAAC
|
Pirinase | Fluticasone propionate (Nasal) | Ear, Nose and Oropharynx | 696 |
|
Pirinase Hayfever Relief for Adults 0.05% nasal spray
1202010M0BDABAC
|
Pirinase | Fluticasone propionate (Nasal) | Ear, Nose and Oropharynx | 155 |
|
Boots Pharmacy Hayfever and Allergy 50microg/dose nsl spy
1202010M0BEAAAC
|
Boots Pharmacy Hayfever and Allergy | Fluticasone propionate (Nasal) | Ear, Nose and Oropharynx | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.